AMA warns pharmacy prescribing undermines AMR stewardship

4 minute read


Governments are seeking more judicious antimicrobial use while simultaneously funding antibiotic prescribing in community pharmacies, the AMA says.


Despite the government’s calls for more appropriate, evidence-based antimicrobial prescribing, the expansion of new pathways in community pharmacy outside Medicare and PBS is forcing “gaps in implementation and policy coherence”, the AMA says.   

In its latest report on antimicrobial resistance (AMR) in Australia, released today, the AMA noted that under state-based frameworks, some pharmacists can still prescribe trimethoprim for uncomplicated cystitis without a GP prescription.  

But its concern went beyond state and federal tensions. The Women’s Health Trial widened access to uncomplicated UTI treatment to all women in October, with the trial set to commence in February 2027, outside the mechanisms used to monitor and support appropriate use, the AMA said.  

In previous trials, most women received antibiotics, despite the possibility of other infections or non-bacterial causes of dysuria and urinary frequency, AMA president Dr Michael Bonning told The Medical Republic.   

“We make the call about pharmacy prescribing because in general practice, we use broader diagnostic approaches, which allow us to consider factors beyond a relatively narrow scope. And because of that, we often err away from prescribing antibiotics,” Dr Bonning said.  

While 88.1% of last-line antibiotics in Australian hospitals were prescribed appropriately in 2024, and antibiotic use is now roughly 21% lower than a decade ago, community expansions without sufficient guardrails risk reversing progress, the AMA warned.  

In 2024, reports of critical antibiotic resistance increased by 25.2%.  

“Antimicrobial resistance is reaching one of those important tipping points because we are starting to see more and more deaths directly attributable to significant antibiotic resistance,” Dr Bonning said.   

The AMA put forth four priorities – funding the implementation of strategies already outlined; strengthening stewardship across all healthcare settings to protect responsible prescribing; improving public literacy about AMR; and advancing antimicrobial innovation and access.  

Across the four priorities, the AMA outlined 14 priority actions for leading agencies, with timelines and measurable targets. 

They included a national target for reducing inappropriate prescribing, to be set by 2028, with annual progress reports by the Australian Commission on Safety and Quality in Health Care, the Australian Centre for Disease Control (CDC), and state and territory health departments from 2027.  

“We’re not publicly reporting against established performance measures. We don’t have the accountability mechanisms across jurisdictions,” Dr Bonning said.   

This included extending funding for Antimicrobial Use and Resistance in Australia (AURA) and addressing prescribing data gaps among private and non-GP providers, including annual public reporting on the appropriateness of surgical prophylaxis and its prolonged use in aged care. 

The AMA also called for national funding to make current pilot AMR audit programs in general practice permanent, with PHNs to deliver them from 2027 to 2030.  

On innovation, the AMA said implementing the subscription-style reimbursement model recommended by the HTA Policy and Methods Review would help address the shrinking number of new antimicrobials reaching the market as AMR increases.  

Dr Bonning said pharmacy companies had little incentive to invest because antibiotics were short course medications rather than “blockbusters”.  

Without government funding, he said Australia risked being at the bottom of the global research and development supply chain and potentially lacking access to advanced antibiotics for years after market release.  

“We’ve got to do more in the profession of medicine to assist antimicrobial literacy,” Dr Bonning said.  

When it came to GPs, he emphasised the importance of “being willing to have those more difficult conversations”, including warning patients against saving their antibiotics for “next time”.   

Read the full report here. 

End of content

No more pages to load

Log In Register ×